n-(2-hydroxypropyl)methacrylamide has been researched along with Melanoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hlousková, D; Hrkal, Z; Oleár, T; Plocová, D; Poucková, P; Soucek, J; Strohalm, J; Ulbrich, K; Zadinová, M | 1 |
| Connors, TA; Duncan, R; Satchi, R | 1 |
| Brereton, M; Duncan, R; Maeda, H; Miyamoto, Y; Seymour, LW; Strohalm, J; Ulbrich, K | 1 |
3 other study(ies) available for n-(2-hydroxypropyl)methacrylamide and Melanoma
| Article | Year |
|---|---|
Polymer conjugated bovine seminal ribonuclease inhibits growth of solid tumors and development of metastases in mice.
Topics: Animals; Antineoplastic Agents; Cattle; Dose-Response Relationship, Drug; Drug Carriers; Endoribonucleases; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Polymethacrylic Acids | 2001 |
PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.
Topics: Animals; Area Under Curve; Cathepsin B; Combined Modality Therapy; Enzyme Activation; Half-Life; Infusions, Intravenous; Male; Melanoma; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Polymethacrylic Acids; Prodrugs; Skin Neoplasms | 2001 |
Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier.
Topics: Acrylamides; Animals; Drug Carriers; Iodine Radioisotopes; Macromolecular Substances; Male; Melanoma; Metabolic Clearance Rate; Mice; Molecular Weight; Neoplasms, Experimental; Sarcoma, Experimental; Tumor Cells, Cultured | 1995 |